MMB-CHMINACA

The following information was compiled in April 2026 and is subject to change as new research is conducted and as new information becomes available:

Description: MMB-CHMINACA is a synthetic cannabinoid bearing structural similarity to other indazole-based synthetic cannabinoids (e.g., MDMB-CHMINACA, AB-CHMINACA, MAB-CHMINACA). MMB-CHMINACA is reported to be a potent cannabinoid receptor agonist (CB₁: pEC₅₀=8.64±0.09, E_max=115%; CB₂: pEC₅₀=9.92±0.08, E_max=80%) with greater efficacy and potency in comparison to delta-9 THC (CB₁: pEC₅₀=7.47±0.16, E_max=51%; CB₂: pEC₅₀=6.62±0.25, E_max=21%).² MMB-CHMINACA pharmacological potency falls in range of other reported synthetic cannabinoids at cannabinoid (CB₁: EC₅₀=0.45-36 nM, CB₂: EC₅₀=4.6-128 nM) receptors in the brain.^1-3 MMB-CHMINACA was first identified at the CFSRE in a urine specimen received from Michigan and was detected alongside other synthetic cannabinoids. MMB-CHMINACA is not currently a scheduled drug in the United States.

Class:

Cannabinoid

Appearance:

Toxicology

Formula:

C21H29N3O3

MW:

371.5

[M+]:

371

[M+H]+:

372.2282

IUPAC:

N-[[1-(cyclohexylmethyl)-1H-indazol-3-yl]carbonyl]-valine, methyl ester

Report Date:

April 7, 2026